OpenLegislation

Division 3.4.2.2.4.1 F1

United Kingdom

Original text. Later amendments are not shown.

For classification of a substance, evidence should include any or all of the following using a weight of evidence approach:

  1. (a)

    positive data from patch testing, normally obtained in more than one dermatology clinic;

  2. (b)

    epidemiological studies showing allergic contact dermatitis caused by the substance. Situations in which a high proportion of those exposed exhibit characteristic symptoms are to be looked at with special concern, even if the number of cases is small;

  3. (c)

    positive data from appropriate animal studies;

  4. (d)

    positive data from experimental studies in man (see section 1.3.2.4.7);

  5. (e)

    well documented episodes of allergic contact dermatitis, normally obtained in more than one dermatology clinic;

  6. (f)

    severity of reaction may also be considered.

Annotations

Textual amendments

F1

Substituted by Commission Regulation (EU) No 286/2011 of 10 March 2011 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance).